19 Mar

Exploring Analysts’ Views on GlaxoSmithKline

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts have set GlaxoSmithKline’s (GSK) 12-month consensus target price at $44.33, 9.48% higher than the stock’s closing price on March 18. Analysts’ consensus recommendation for the stock is a “buy.” In 2019, analysts have revised the company’s target price upward once, from $44.00 in January to $44.33 in March.

To learn about GlaxoSmithKline’s key growth drivers this year, read What Are the Key Growth Drivers for GlaxoSmithKline in 2019?

Exploring Analysts’ Views on GlaxoSmithKline

Of the four analysts covering GlaxoSmithKline, two have given it “strong buys,” and two have given it “holds.” The highest target price estimate for the company is $46, and the lowest is $42.

On March 18, GlaxoSmithKline closed at $40.49, 0.34% lower than its previous closing price, 12.07% higher than its 52-week low of $36.13, and 4.41% lower than its 52-week high of $42.36. The company’s market cap is $98.86 billion.

Based on its closing price on March 18, GlaxoSmithKline has reported returns of 1.02% in the last week, -0.91% in the last month, and 6.72% in the last quarter. The company has reported returns of 2.95% in the last half year, 9.67% in the last year, and 5.97% year-to-date.

Revenue and EPS estimates

Analysts expect GlaxoSmithKline’s revenue to see YoY (year-over-year) changes of -2.40% to $9.81 billion in the first quarter, 0.74% to $10.01 billion in the second quarter, 2.34% to $10.79 billion in the third quarter, and 1.47% to $10.70 billion in the fourth quarter of 2019. Analysts also expect the company’s non-GAAP (generally accepted accounting principles) EPS to see YoY changes of -4.35% to $0.66 in the first quarter, -13.92% to $0.68 in the second quarter, -10.87% to $0.82 in the third quarter, and -6.29% to $0.76 in the fourth quarter.

Analysts expect GlaxoSmithKline’s revenue to see YoY rises of 1.69% to $41.78 billion in 2019, 1.92% to $42.58 billion in 2020, and 3.69% to $44.16 billion in 2021. Analysts also expect the company’s non-GAAP EPS to see YoY changes of -5.82% to $2.92 in 2019, 6.50% to $3.11 in 2020, and 16.27% to $3.62 in 2021.

Latest articles

21 May

Trump’s Huawei Ban Pulls Down US Chip Stocks

WRITTEN BY Scarlett Ness

Last week, Donald Trump blacklisted Chinese telecom giant Huawei Technologies amid rising US-China trade tensions.

21 May

Snap Is Making Up for Last Year

WRITTEN BY Sean Allen

This year has been a great one for Snapchat parent Snap (SNAP), and its stock has nearly doubled.

Coca-Cola (KO) will offer a limited edition of its of New Coke cans beginning May 23 as part of its partnership with Netflix’s (NFLX) show Stranger Things.

21 May

Why Clorox Stock Is Underperforming Peers

WRITTEN BY Adrian Stevens

Clorox stock (CLX) is down about 8% since the company posted its third quarter of fiscal 2019 earnings on May 1.

21 May

What JD Is Set to Get from Its Xinning Deal

WRITTEN BY Rachel Gunter

JD.com (JD) recently invested ~$55 million in purchase a ~10% stake in Jiangsu Xinning Modern Logistics, a Chinese logistics company focusing on the consumer electronics supply chain.

Today, the US stock market was on a path of recovery after starting the week on a bearish note yesterday.

172.31.1.77